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ttp://dx.doi.org/10.1016/j.jmoldx.2014.03.006The identiﬁcation of recurrent gene rearrangements in the clinical laboratory is the cornerstone for risk
stratiﬁcation and treatment decisions in many malignant tumors. Studies have reported that targeted
next-generation sequencing assays have the potential to identify such rearrangements; however, their
utility in the clinical laboratory is unknown. We examine the sensitivity and speciﬁcity of ALK and
KMT2A (MLL) rearrangement detection by next-generation sequencing in the clinical laboratory. We
analyzed a series of seven ALK rearranged cancers, six KMT2A rearranged leukemias, and 77 ALK/KMT2A
rearrangementenegative cancers, previously tested by ﬂuorescence in situ hybridization (FISH).
Rearrangement detection was tested using publicly available software tools, including Breakdancer,
ClusterFAST, CREST, and Hydra. Using Breakdancer and ClusterFAST, we detected ALK rearrangements in
seven of seven FISH-positive cases and KMT2A rearrangements in six of six FISH-positive cases. Among
the 77 ALK/KMT2A FISH-negative cases, no false-positive identiﬁcations were made by Breakdancer or
ClusterFAST. Further, we identiﬁed one ALK rearranged case with a noncanonical intron 16 breakpoint,
which is likely to affect its response to targeted inhibitors. We report that clinically relevant chro-
mosomal rearrangements can be detected from targeted gene panelebased next-generation sequencing
with sensitivity and speciﬁcity equivalent to that of FISH while providing ﬁner-scale information and
increased efﬁciency for molecular oncology testing. (J Mol Diagn 2014, 16: 405e417; http://
dx.doi.org/10.1016/j.jmoldx.2014.03.006)Supported by the Department of Pathology, Washington University, and
by the National Institutes of Health grant K12HL087107-07 (E.J.D.).
Disclosures: None declared.The detection of recurrent chromosomal rearrangements by
cytogenetics was one of the earliest clinical molecular
oncology assays and continues to play a major role in cancer
diagnosis and prognosis.1,2 Although translocations in the
clinical laboratory are generally detected by cytogenetics,
ﬂuorescence in situ hybridization (FISH), or RT-PCR,
studies have demonstrated that they may also be detected
by next-generation sequencing (NGS) of DNA or RNA.3e5
DNA-level translocations can be detected in particular areas
of interest by ﬁrst performing hybrid capture enrichment to
target one or both partner genes in a translocation, followed
by NGS.4,6 NGS-based translocation detection has several
advantages over conventional clinical laboratory methods,
such as the ability to precisely deﬁne the breakpoint region,
detect cryptic rearrangements and unknown partner genes,
and run in parallel with gene mutation detection.stigative Pathology
.Chromosomal rearrangements are detected in the clinical
laboratory by routine cytogenetics, FISH, or RT-PCR; how-
ever, these methods have limitations. Cytogenetic studies,
including chromosome analysis and metaphase FISH, require
actively dividing cells, which can be especially difﬁcult to
obtain from solid tumors. In addition, chromosome analysis
is of limited resolution, particularly in oncology specimens,
and is therefore insensitive to cryptic and complex rear-
rangements.5,7,8 Some rearrangements can be assayed via
RNA-based RT-PCR methods, but this approach is less
useful for translocations with a large number of partner genes
or those with potentially diverse breakpoints.9,10 FISH is
Abel et alamong the most commonly used laboratory methods for the
detection of chromosomal rearrangements and offers high
sensitivity and the ability to test routine interphase, formalin-
ﬁxed, parafﬁn-embedded (FFPE) tissue sections. However,
FISH relies on highly trained individuals to score rear-
rangements by ﬂuorescent microcopy and is an inherently
low-resolution method that may be confounded by complex,
multiway rearrangements and may require numerous probes
to fully elucidate translocation partners for promiscuous
genes, such as KMT2A.5,10 Finally, FISH results are generally
difﬁcult to validate by orthogonal methods, outside less
sensitive cytogenetic assays.
Two of the most commonly tested translocations in the
clinical laboratory are for rearrangements of the anaplastic
lymphoma kinase gene, ALK, in nonesmall cell lung cancer
and of the mixed-lineage leukemia gene, KMT2A (formerly
known as MLL), in acute leukemia. The EML4-ALK fusion
results from an inversion event on chromosome 2p that
generally causes an in-frame fusion of EML4 exons 1 to 13 to
ALK exons 20 to 29, producing an aberrant fusion gene with
constitutive kinase activity, sensitive to crizotinib.11e14 The
occurrence of ALK fusions and other common lung cancer
gene mutations in KRAS and EGFR are generally considered
to be mutually exclusive, arguing that these tumors represent
a distinct subset of lung cancers.15 Although not pharmaco-
logically targetable, KMT2A rearrangements are of diagnostic
and prognostic signiﬁcance in acute leukemias, including
both acute myeloid leukemia (AML) and acute lymphocytic
leukemia (ALL).16,17 KMT2A rearrangements can be readily
detected by FISH using break-apart probes; however, eluci-
dation of the translocation partner gene may be difﬁcult
because >100 have been identiﬁed.10,18
NGS has had a tremendous effect on cancer discovery
and is now becoming routine in the clinical molecular
oncology laboratory.3,19e21 NGS allows for the cost-
effective, simultaneous evaluation of numerous sequence
variants as part of focused clinical oncology panels or whole
exomes. We and other groups have previously found that a
range of DNA variants, including translocations, insertions
or deletions, and copy number variants, can be detected
from targeted NGS data and that it is possible to identify
DNA-level breakpoints with single-nucleotide preci-
sion.4,22,23 However, to be useful in the clinical setting, a
thorough evaluation of the sensitivity and speciﬁcity of
structural variation (SV) detection by NGS compared with
standard methods is required. Given that numerous potential
translocations can be evaluated by NGS simultaneously as
part of a larger NGS cancer panel, for little to no additional
cost, such methods could provide a signiﬁcant savings for
laboratories that perform multiple single-gene tests and
multiple FISH assays on oncology specimens.
We present a comprehensive evaluation of targeted trans-
location detection by NGS in the clinical laboratory by
comparing four publicly available translocation detection
tools (including the laboratory derived ClusterFAST) on
targeted NGS data from 13 cases with ALK or KMT2A406rearrangements (six lung carcinomas and one anaplastic large
cell carcinoma with ALK rearrangements; six leukemias with
KMT2A rearrangements) and 77 cancers negative for ALK
and KMT2A rearrangements by FISH. We found that trans-
locations can be reliably detected at the DNA level by tar-
geted NGS panels and that such methods offer sensitivity and
speciﬁcity similar to that of routine FISH with the advantage
of single-nucleotide breakpoint resolution. Further, we
examine approaches to designing capture probes for targeted
NGS evaluation, evaluate the minimal coverage levels
necessary to detect translocations, and explore methods to
reduce false-positive translocation reports.
Materials and Methods
Sample Selection
A total of six FFPE lung adenocarcinomas and one
anaplastic large cell lymphoma that had previously tested
positive for ALK rearrangements by FISH and six KMT2A
rearranged acute leukemias were used as positive controls.
The ALK rearranged cases were selected from the Wash-
ington University Cytogenomics and Molecular Pathology
Laboratory (two cases), ARUP References Laboratories
(three cases), and the University of Washington (two cases).
ALK rearranged positive controls were selected on the basis
of remaining tissue available for sequence analysis; cases
were not excluded based on FISH results (ie, the percentage
of positive nuclei or the presence of complex rearrange-
ments). The mean tumor cellularity of ALK rearranged cases
was 40% (range, 30% to 50%) by morphologic estimate
(slides for ﬁve of seven cases were available for morpho-
logic review). The KMT2A rearranged acute leukemias were
selected from the Washington University Cytogenomics and
Molecular Pathology Laboratory based on availability of the
remaining specimen in the form of a ﬁxed cell pellet derived
from a bone marrow aspirate from which DNA was ob-
tained. The mean tumor cellularity of KMT2A rearranged
cases was 90% (range, 75% to 100%) based on FISH or
cytogenetics. A total of 77 consecutive control samples
negative by FISH for ALK and KMT2A rearrangements were
identiﬁed from the Washington University Genomics and
Pathology Services (GPS) Laboratory. All negative control
cases were evaluated by KMT2A and ALK break-apart FISH
probes and by the same panel-based NGS as FISH-positive
cases in a College of American Pathologists and Clinical
Laboratory Improvement Amendments accredited labora-
tory (GPS). This study was approved by the Human Studies
Committee of Washington University School of Medicine
(institutional review board approval 201101733).
Evaluation by FISH
Locus-speciﬁc FISH for ALK (2p23) and KMT2A (11q23)
was performed on FFPE solid tumors or ﬁxed cell pellets
derived from hematologic specimens. The ALK and KMT2Ajmd.amjpathol.org - The Journal of Molecular Diagnostics
Translocation Detection by NGSloci were assayed using the LSI ALK Dual Color Break
Apart Rearrangement Probe and the LSI KMT2A (MLL)
Dual Color Break Apart Rearrangement Probe (Abbott
Molecular, Abbott Park, IL). Hematologic specimens pro-
bed for KMT2A consisted of slides prepared from a cell
suspension ﬁxed in 3:1 methanol:acetic acid. Slides were
ﬁrst treated with 2 standard saline citrate (SSC) at 72C,
followed by an ethanol dehydration series (70%, 85%, and
100%) before applying 10 mL of a 1:10 dilution of probe:-
hybridization buffer. Sealed, coverslipped slides were
placed in a Thermobrite (Abbott Molecular) to allow for co-
denaturation of specimen and probe at 72C followed by
overnight hybridization at 37C. Slides were washed in
0.3% NP-40/0.4 SSC and 0.1% NP-40/2 SSC before
application of DAPI II counterstain (Abbott Molecular).
Slides were examined using an Olympus BX60 ﬂuorescent
microscope (Olympus America, Center Valley, PA) equip-
ped with a Chroma 82000 ﬁlter set with appropriate ﬁlters
for SpectrumOrange, SpectrumGreen, and DAPI counter-
stain. Images were captured using a CoolSnap camera
(Nikon USA, Melville, NY) and processed with Cytovision
software (Leica Biosystems, Buffalo Grove, IL).
FFPE solid tumor specimens probed for ALK consisted
of 5-mm tissue sections mounted on positively charged
slides. Specimens were deparafﬁnized using Citrosolv and
dehydrated in 100% ethanol before pretreatment using
Vysis Parafﬁn Pretreatment IV kit components (Abbott
Molecular), including pretreatment solution (1N sodium
thiocyanate), and protease pretreatment, consisting of
Vysis Protease IV (pepsin, 2500 to 4000 U/mg) and Vysis
Protease Buffer IV (0.1N hydrochloride). After an ethanol
dehydration series (70%, 85%, and 100%), slides were air-
dried, and 10 mL of probe mixture was applied. Sealed,
coverslipped slides were then placed in a 73C slide moat
(Boekel Scientiﬁc, Feasterville, PA) to allow for co-
denaturation of specimen and probe, followed by over-
night hybridization at 37C. Posthybridization washing
was performed using Vysis Wash Buffer I (0.3% NP-40/
0.7 SSC) and Vysis Wash Buffer II (0.1% NP-40/2
SSC) (Abbott Molecular) before counterstaining with
DAPI I (Abbott Molecular). Slides were examined using an
Olympus BX60 or BX61 ﬂuorescent microscope with
appropriate ﬁlters for SpectrumOrange, SpectrumGreen,
and the DAPI counterstain. The signal patterns were
documented using a CoolSnap camera and CytoVision
Imaging System (Leica Biosystems).
Design of Capture Panel
Targeted sequencing was performed using the GPS V2
gene set. This panel comprises all exons of 151 genes, as
well as the intronic breakpoint regions of ALK and
KMT2A: introns 7 to 12 of KMT2A and introns 16 to 21 of
ALK. Translocation partners (eg, EML4, MLLT3, and
AFF1) were not directly targeted by the capture panel
(Supplemental Table S1).The Journal of Molecular Diagnostics - jmd.amjpathol.orgTargeted NGS
DNA was extracted from FFPE sections (ALK rearranged
cancers) or bone marrow aspirates (KMT2A rearranged
leukemias) and 500 to 1000 ng of DNA prepared for Illu-
mina sequencing as previously described.24 Libraries were
then captured using the GPS version 2 gene set. Captured
DNA was then indexed using limited cycle PCR and
sequenced in multiplex (2 to 15 cases per lane) on a HiSeq
2000 or MiSeq (both from Illumina, Inc., San Diego, CA).
Base calls were made using the included Cassava software
version 1.7. The resulting FASTQ ﬁles were aligned to
National Center for Biotechnology Information build 37.2
of the human reference genome (hg19) using Novoalign
version 2.08 (Novocraft, Selangor, Malaysia) with default
paired-end parameters. Sequence data were cleaned to
remove duplicate reads, recalibrate quality scores, and
realign around known polymorphisms using the Genome
Analysis Toolkit (GATK; version 1.6) (http://www.
broadinstitute.org/gatk, last accessed July 1, 2013) and
Picard tools (version 1.88) MarkDuplicates (http://
sourceforge.net/projects/picard/ﬁles, last accessed July 1,
2013) according to the GATK best practices guidelines.25
Quality metrics were calculated using the BEDTools
(http://code.google.com/p/bedtools, last accessed July 1,
2013) and Samtools (http://samtools.sourceforge.net, last
accessed July 1, 2013) software packages.26,27
Translocation Detection
Translocations were detected from aligned binary sequence
alignment ﬁles using a battery of publicly available software
tools, including BreakDancer version 1.1_2011_02_21,
CREST version 1.0.1, Hydra version 0.5.3, and the
laboratory-derived ClusterFAST version 0.2 (available on
request).28e30 An overall comparison of tools is summarized
in Table 1. Translocation software is reviewed elsewhere,
but, brieﬂy, translocation detection software can be divided
in two general categories: discordant paired-end read
methods (including Breakdancer and Hydra) and split-read
methods (including CREST).31 Discordant paired-end read
methods rely on the presence of read pairs where ends map
to different chromosomes or, in the case of intra-
chromosomal translocations, to the same chromosome but in
the wrong orientation or the wrong distance apart
(Figure 1A). Breakdancer detects SV by identifying pairs of
regions connected by multiple anomalous read pairs and
assigns to each breakpoint a score based on a Poisson
model. Hydra also detects SV from clusters of discordant
read pairs but ﬁrst performs a sensitive realignment to allow
for detection of SVs that occur in repetitive regions of the
genome. Split-read methods typically provide increased
speciﬁcity of SV detection by requiring single-end reads
that span the translocation breakpoint and have the added
advantage of single-base breakpoint accuracy. CREST
identiﬁes breakpoints by assembly and remapping of407
Table 1 Comparison of Translocation Detection Tools
Tool Detection method Description
Determines
breakpoint
Relative speed and
memory requirements
Breakdancer Discordant pair Breakpoint identified by discordant read pairs
Provides confidence score based on Poisson model
No Fast/minimal memory
required
ClusterFAST Discordant pairs
and split reads
Breakpoint approximated by discordant reads pairs
Breakpoints confirmed by split single-end reads to
determine exact position
Search for structural variation is restricted to
prespecified target region
Yes/outputs
breakpoint
spanning contig
Fast/minimal memory
CREST Split reads Locates clusters of soft-clipped reads generated during
initial read
Assembles and remaps soft-clipped reads to determine
exact breakpoint
Yes/outputs
breakpoint
spanning contig
Slow/minimal memory
Hydra Discordant pair After sensitive realignment to allow additional
mismatches and multiply mapped reads, breakpoints
identified by discordant read pairs
No, but gives
good
approximation
with high
coverage level
Slow, large memory
requirement for
sensitive realignment
Abel et alclusters of soft-clipped reads (Figure 1B). We developed the
ClusterFAST tool speciﬁcally for the detection of SV from
targeted NGS data. It makes use of information from both
discordant pairs and split reads. It ﬁrst identiﬁes clusters of
discordant pairs, then splits and remaps to the genome the
unmapped or soft-clipped partners of reads mapping in the
vicinity of the discordant pair cluster (Figure 1C). If
discordant pairs among the remapped short reads corrobo-
rate breakpoints identiﬁed in the original set of discordant
pair clusters, all discordant pairs and partially mapped reads
from the region are assembled, using Pindel and Velvet, to
form breakpoint-spanning contigs.32,33 These contigs are
then mapped to the human genome using BLAT version 35
to determine the exact coordinates of the breakpoint.34
Although our targeted region was sequenced to high
coverage on average, we observed areas of low coverage in
some of the GC-rich intronic regions where translocations are
known to occur. Thus, for each of the bioinformatic tools, we
chose parameters to maximize sensitivity (exact commands
used to run each tool provided in Supplemental Table S2).
For Breakdancer and Hydra, we required a minimum of two
supporting pairs to report a breakpoint; for ClusterFAST, two
supporting pairs and one split read; and for CREST, two split
reads. We then ﬁltered the results to identify only structural
variants larger than 1 kb, occurring within 50 kb of ALK or
KMT2A. For Breakdancer and CREST, we applied read
depth ﬁlters at 5000 reads to exclude regions of nonspeciﬁc
alignment. For Hydra, which is designed to be sensitive to SV
in repetitive regions, we ﬁltered the results to require at least
one supporting read pair be uniquely mapped.
Evaluation of Results
Because the level of resolution of breakpoint detection by
NGS and FISH differs by several orders of magnitude, we
developed criteria for deciding concordance between the408two. All FISH results involved break-apart probes (and
therefore did not indicate the partner locus). Thus, we
considered NGS results to be concordant with FISH if we
detected an interchromosomal translocation or SV size >50
kb within 50 kb of ALK or KMT2A. For the cases with
KMT2A rearrangements, we considered the NGS results to
be concordant with cytogenetics if we detected a rear-
rangement in which both members fell within 50 kb of the
speciﬁed cytogenetic band. Finally, we considered the NGS
breakpoint to involve a previously known partner if one side
of the breakpoint fell within 50 kb of ALK or KMT2A and
the other within 50 kb of any gene on a list of previously
reported ALK and KMT2A translocation partners obtained
from the online Atlas of Genetics and Cytogenetics (http://
atlasgeneticsoncology.org//Genes/ALK.html and http://
atlasgeneticsoncology.org//Genes/MLL.html, last accessed
March 1, 2013). A list of translocation partners is included
in Supplemental Tables S3 and S4. All statistical analyses
were performed using the R statistical package (version
2.15.1; R Project for Statistical Computing, http://www.r-
project.org).
Validation of Computationally Predicted Breakpoints
Experimental validation was performed, when sufﬁcient
DNA remained, for breakpoints that met any of three
criteria: i) the breakpoint was detected by at least two bio-
informatic tools, ii) the breakpoint involved a known partner
gene from the Atlas of Genetics and Cytogenetics, and/or
iii) the breakpoint was supported by cytogenetic ﬁndings.
First, PCR primers spanning both sides of the predicted
breakpoint were constructed. PCR was then performed
using standard methods on both the case and a negative
control to ensure amplicon speciﬁcity. PCR products were
then direct sequenced by bidirectional Sanger sequencing
after treatment with exoSAP (Affymetrix, Santa Clara, CA).jmd.amjpathol.org - The Journal of Molecular Diagnostics
Translocation Detection by NGSResults
Depth of Coverage between Rearrangement Positive
and Negative Cases
We ﬁrst examined the coverage over the targeted regions in the
positive and negative controls. The mean depth of coverage
across the full 151-gene panel was 1036 (SD, 339; range,
182 to 2488). No signiﬁcant difference was found in
overall coverage depth in positive (mean, 1085; range, 306
to 1493) compared with negative controls (mean, 1028;
range, 182 to 2488;PZ 0.62, Student’s t-test). Owing to the
difﬁculty in capturing the largely intronic breakpoint regions
compared with the overall (exon-rich) capture panel, the
coverage over the ALK breakpoint region (mean, 691; range,Figure 1 A comparison of bioinformatic tools for translocation detection. A:
translocations in NGS data and is the main method used by Breakdancer and Hydra
pair maps to the chromosome of interest and the other maps to a different chrom
methods can approximate the position of the breakpoint to within approximatel
B: Soft-clipped reads are generated during sequence alignment when the far end o
further analysis. With CREST, translocations are identiﬁed in areas where increa
spanning the translocation breakpoint. Breakpoint sequences are then aligned ba
ClusterFAST uses a split single end read method to identify translocations that con
similar to Breakdancer and Hydra. In the second phase, putative translocations a
(soft-clipped) that map in the vicinity of the translocation. These reads are then s
mapped. If the reads are mapped and also span the breakpoint, a contig is produce
to the reference genome.
The Journal of Molecular Diagnostics - jmd.amjpathol.org186 to 1351; P Z 2.2  1016, paired t-test) was signiﬁ-
cantly reduced compared with the overall mean coverage.
Similarly, the coverage over the targeted KMT2A rearrange-
ment region was signiﬁcantly decreased (mean, 583; range,
221 to 1124; P < 2.2  1016, paired t-test) compared with
the overall mean coverage. However, no signiﬁcant difference
was found in depth of coverage in the targeted ALK rear-
rangement target region between FISH-positive and -negative
controls (positive controls: mean, 767; range, 218 to 1120;
negative controls: mean, 678; range, 186 to 1351; PZ 0.31)
or in the targetedKMT2A breakpoint region (positive controls:
mean, 562; range, 221 to 844; negative controls: mean,
587; range, 228 to 1124; PZ 0.65).
Because the sensitivity of breakpoint detection depends
not on the mean coverage but on the coverage local to theDiscordant read pair mapping is the simplest approach for identiﬁcation of
. Using this approach, we detected rearrangements when one end of a read
osome or the same chromosome at a greater than expected distance. Such
y 100 bp but do not generate a contig of the actual breakpoint sequence.
f the read does not match the reference sequence and is then masked from
sed soft-clipped reads are identiﬁed and can be assembled into a contig
ck to the reference genome to determine the position of the breakpoint. C:
sists of three phases. In the ﬁrst phase, discordant read pairs are identiﬁed
re further evaluated by ﬁnding one end anchored or partially mapped reads
plit into artiﬁcial read pairs and realigned to determine whether they can be
d by assembling all local reads in the area. This contig is then mapped back
409
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Figure 2 Percentage of bases in the targeted breakpoint hotspots for
ALK and KMT2A covered at levels ranging from 5 to 1000 for all positive
controls. The box and whisker plots represent the median and upper and
lower quartiles for the 13 rearranged cases.
Abel et albreakpoints, we examined the depth of coverage proﬁles for
the ALK and KMT2A rearranged cases across the targeted
intronic rearrangement regions in ALK and KMT2A.
Figure 2 shows the percentage of bases covered at each of
several thresholds ranging from 5 to 1000 for the ALK
and KMT2A breakpoint hotspots. For the ALK gene, the
median coverage across all cases was >50 for 99.9% of
the targeted region but exceeded 200 for only 95.1% of
positions. Similarly, in the KMT2A gene, 96.9% of nucle-
otides were covered to at least 50 based on the median
over all cases, whereas only 80% were covered to at least
200. In the targeted region of KMT2A, the variability in
depth of coverage was in part due to variability in GC
content; regions of low coverage corresponded to
regions of high GC content (Pearson’s r Z 0.18,
P Z 3.9  1013; Figure 3). In contrast, variable GC
content had no signiﬁcant effect on depth of coverage in the
targeted region of the ALK gene (r Z 4.4  104;
P Z 0.99). We further examined the mappability in the
targeted capture regions, using the Centre for Genomic
Regulation (Barcelona, Spain) alignability tracks obtained
via the University of California, Santa Cruz, genome
browser and found a signiﬁcant negative correlation be-
tween depth of coverage and alignability in both the ALK
(Pearson’s r Z 0.28, P < 2.2  1016) and KMT2A target
regions (r Z 0.56; P < 2.2  1016).35410Evaluation of Bioinformatic Tools for Translocation
Detection
We next examined the performance of four bioinformatic
tools for translocation detection using 13 cases with known
ALK or KMT2A translocations identiﬁed by FISH. We
tested the BreakDancer, Hydra, CREST, and ClusterFAST
software tools, which identify potential structural variants
from discordant read pairs and/or split reads (see Materials
and Methods for a description of tools). Because trans-
locations were initially detected using a FISH break-apart
assay and therefore the precise breakpoints were un-
known, we considered NGS results to be concordant with
FISH if any interchromosomal or intrachromosomal trans-
location was detected that was >50 kb and occurred within
50 kb of the ALK or KMT2A gene loci.
By NGS, we detected an ALK rearrangement in seven of
seven cases positive for ALK rearrangement by FISH (100%
sensitivity; 95% CI, 65%e100%; Wilson score interval). In
all seven cases, the rearrangement involved a known partner
of ALK: EML4 in the six lung carcinomas and NPM1 in the
single anaplastic large cell carcinoma (Table 2). Both
Breakdancer and ClusterFAST identiﬁed an ALK rear-
rangement that involved a known partner in all seven cases;
these were subsequently validated by PCR and Sanger
sequencing. Hydra identiﬁed an ALK rearrangement in
seven of seven cases but in one case identiﬁed a novel
partner (DNMT3A) rather than EML4. This ﬁnding may
indicate a complex, multiway rearrangement; however, we
were unable to validate this breakpoint by PCR. The
CREST software package gave slightly lower concordance
with FISH, identifying an ALK rearrangement in only ﬁve of
seven cases (71% sensitivity; 95% CI, 36%e92%).
Sensitivity of KMT2A rearrangements by NGS was
similar, with six of six FISH-positive cases identiﬁed by NGS
(100% sensitivity; 95% CI, 61%e100%) (Table 3). In all six
cases, we detected a rearrangement that involved a known
partner of KMT2A, including AFF4 (AF4), MLLT6, MLLT1
(ENL), MLLT3 (AF9), and MLLT10 (AF10). Furthermore,
the three informatic tools (Breakdancer, Hydra, and Clus-
terFast) were consistent, reporting the same rearrangements
and the same partners in all cases. Again, CREST had slightly
lower sensitivity, detecting any KMT2A rearrangement in
ﬁve of six (83% sensitivity; 95% CI, 44%e99%) KMT2A
rearranged cases and detecting a rearrangement that involved
a known partner in only three of six (50% sensitivity; 95%
CI, 19%e81%) of cases. Among the six detected rear-
rangements, ﬁve were consistent with cytogenetics and were
subsequently validated by PCR and Sanger sequencing. In
the remaining case, we detected by NGS a t(9;11)(p21;q23)
KMT2A/MLLT3(AF9) translocation and a t(9;11)(p24;q23)
secondary event, which is inconsistent with the cytogenetic
ﬁnding of t(1;11)(p22;q23)del(9)(p22). This discrepant result
likely represents a multiway translocation in which a small
fragment of chromosome 9 was inserted near the chromo-
some 1 and 11 rearrangement. Although attempts to validatejmd.amjpathol.org - The Journal of Molecular Diagnostics
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Figure 3 Coverage proﬁles within the targeted breakpoint hotspots for ALK and KMT2A. The interquartile range of coverage depth at each position (blue-
gray), percentage of GC content (black), and alignability (CRG 50; gray) over the targeted capture region (exons as dark blue boxes) are shown. Breakpoints
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Translocation Detection by NGSthis breakpoint by PCR and Sanger sequencing were un-
successful because of insufﬁcient remaining DNA, we note
that the same translocation was detected by all four tools and
was supported by >50 read pairs and that we were able to
assemble breakpoint-spanning contigs that mapped uniquely
to the reference genome, similar to other PCR-conﬁrmed
translocations.
We next examined the full set of NGS-identiﬁed break-
points among the positive control cases. In total, there were
25 breakpoints (a single breakpoint in one case and two
breakpoints in each of the remaining 12 cases) that satisﬁed
one of the following: i) the breakpoint was detected by two
or more informatic tools, ii) the breakpoint involved a
known partner of ALK or KMT2A, or iii) the breakpoint was
consistent with cytogenetic ﬁndings. To evaluate our ability
to detect structural rearrangements at the single-base level
rather than at the much lower resolution available by FISH,
we attempted PCR validation of each of these breakpoints
when sufﬁcient sample remained. Of the 25 breakpoints, 23
were agreed on by the three bioinformatic tools Break-
dancer, Hydra, and ClusterFAST. The remaining two
breakpoints were each missed by either Breakdancer or
Hydra. We considered as likely false-positive results and did
not attempt to validate by PCR any breakpoints reported by
a single bioinformatic tool and involving an unknown
partner of ALK or KMT2A. There were nine suchThe Journal of Molecular Diagnostics - jmd.amjpathol.orgbreakpoints among all positive controls, none of which were
consistent with cytogenetics: seven reported by Hydra only,
one reported by CREST only, and one reported by Break-
dancer only (Supplemental Figure S1).
From the seven ALK rearranged cases, we detected a total
of 13 breakpoints among all four informatics tools: a single
breakpoint in one case and two distinct breakpoints for each
of the remaining six cases. Of these 13, we validated 12 by
PCR and Sanger sequencing. (Supplemental Table S5). In
all ALK rearranged cases, one of the breakpoints was in the
correct orientation to produce a fusion gene; the second (if
present) represented either a reciprocal event (four of six
cases) or part of a complex event that involved another locus
(two to six cases). The multiway events included a novel
inv(2)(p23) event (involving DNMT3A) and a novel
t(2;20)(p23;q13) event. Finally, we examined the sensitivity
of the four bioinformatic tools in detecting the full set of
breakpoints. ClusterFAST detected all 13 (100%; 95% CI,
77.2%e100%), whereas Breakdancer and Hydra each
detected 12 of 13 (92%; 95% CI, 67%e100%) and CREST
detected 6 of 13 (46%; 95% CI, 23%e71%). Of particular
interest, in one of the lung cancer samples harboring an
ALK-EML4 inversion, the breakpoints were found in intron
16 of ALK rather than the canonical intron 19 (Figure 2).
Among the six KMT2A rearranged leukemias, we detec-
ted a total of 12 breakpoints: two per case, with the second411
Table 2 ALK Rearrangements
Case No. Diagnosis
Detected any ALK rearrangement Detected known ALK partner
ClusterFAST Breakdancer Hydra CREST ClusterFAST Breakdancer Hydra CREST
1 Lung adenocarcinoma Yes Yes Yes No EML4 EML4 EML4 NA
2 Lung adenocarcinoma Yes Yes Yes Yes EML4 EML4 EML4 EML4
3 Lung adenocarcinoma Yes Yes Yes Yes EML4 EML4 EML4 EML4
4 Lung adenocarcinoma Yes Yes Yes No EML4 EML4 NO NA
5 Lung adenocarcinoma Yes Yes Yes Yes EML4 EML4 EML4 EML4
6 Lung adenocarcinoma Yes Yes Yes Yes EML4 EML4 EML4 EML4
7 ALCL Yes Yes Yes Yes NPM1 NPM1 NPM1 NPM1
ALCL, anaplastic large cell lymphoma.
Abel et albreakpoint representing either a reciprocal event (four of six
cases) or a complex event involving a distant partner (two of
six cases) (Supplemental Table S6). The three software tools
Breakdancer, Hydra, and ClusterFAST each detected all 12
unique breakpoints (100% sensitivity; 95% CI, 76%e
100%), whereas CREST detected 6 of 12 (50%; 95% CI,
25%e75%). Nine of the 12 breakpoints were subsequently
validated by PCR and Sanger sequencing. We were unable
to validate the remaining three breakpoints: for two break-
points (from a single case) there was insufﬁcient remaining
DNA; for the ﬁnal breakpoint, we could not design adequate
PCR primers because of the lack of sequence complexity.
Depth of coverage at the detected breakpoints varied widely,
ranging from 98 to 819 (mean, 348.7; SD, 210.6) in
the ALK rearranged cases and from 15 to 1024 (mean,
400.8; SD, 319.2) in the KMT2A rearranged cases
(Figure 2). Also highly variable was the number of discor-
dant read pairs supporting each breakpoint, which ranged
from 2 to 34 (mean, 11.6; SD, 9.3) for the ALK cases and
from 4 to 88 (mean, 41.6; SD, 33.9) for the KMT2A rear-
ranged cases.Table 3 KMT2A Rearrangements
Case
No.
Diag-
nosis Cytogenetics
Detected any KMT2A
rearrangement
Cluster-
FAST
Break-
dancer Hy
8 B-ALL 47,XY,þX,t(4;11)(q21;q23),-6,-8,-17,
þ1w5mar[cp18]/46,XY[2]
Yes Yes Ye
9 AML 45,X,-X,þ1, add(1)(p13),del(1)(q21),
add(3)(q27),-7, t(11;17)(q23;q21)
[15]/46,XX[5]
Yes Yes Ye
10 AML t(11;19)(q23;p13.3) Yes Yes Ye
11 AML 45,X,Y, t(1;11)(p22;q23),del(9)(p22)
[20]
Yes Yes Ye
12 AML 46,XY,add(8)(p21),t(9;11)(q34; q23),
add(12)(p13)[19]//46,XX[1]
Yes Yes Ye
13 B-ALL 46w48,XX,?del(X)(q22),del(1)(q32),
t(4;11)(q21;q23),-5,-6,-7,-13,
þ15,-16,-18,-19,add(19)(p13),
-20,-21,þ22, þ1w4mar[cp19]/
46,XX[1]
Yes Yes Ye
AML, acute myeloid leukemia; B-ALL, B-cell acute lymphocytic leukemia; NA, n
412Effect of Coverage on Breakpoint Detection
To simulate the effects of low tumor cellularity or reduced
coverage on translocation detection sensitivity, we performed
random down-sampling and applied the three best-performing
translocation detection tools (Breakdancer, Hydra, and Clus-
terFAST) to each down-sampled data set. Sampling rates
ranged from 0.9 to 0.05, corresponding to mean coverage levels
over the targeted breakpoint regions of 600 down to 33, and
three random samples were drawn from each case at each
sampling rate (Figure 4 and Supplemental Figure S2). At a
down-sampling rate of 50%, corresponding to a mean coverage
of 332 (SD, 114; range, 110 to 452) over the ALK and
KMT2A targeted regions, all three tools provided at least
92% sensitivity. At a 20% down-sampling rate (mean
coverage, 133; SD, 46; range, 46 to 181), the sensitivity
decreased to 54% to 85% (range over three tools and three
samples per case). At a down-sampling rate of 10% (mean
coverage, 67; SD, 23; range, 22 to 90), the sensitivity
ranged from 38% to 62% over all tools. Across the range of
sampling rates, the three tools exhibited similar sensitivity.Detected known KMT2A partner
dra CREST
Cluster
FAST
Break
dancer Hydra CREST
s Yes AFF4 (AF4) AFF4 (AF4) AFF4 (AF4) AFF4 (AF4)
s No MLLT6 MLLT6 MLLT6 NA
s Yes MLLT1 (ENL) MLLT1 (ENL) MLLT1 (ENL) MLLT1 (ENL)
s Yes MLLT3 (AF9) MLLT3 (AF9) MLLT3 (AF9) No- PTPRD
s Yes MLLT10
(AF10)
MLLT10
(AF10)
MLLT10
(AF10)
No- MED27
s Yes AFF4 (AF4) AFF4 (AF4) AFF4 (AF4) AFF4(AF4)
ot applicable.
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Figure 4 Sensitivity of Breakdancer (black), Hydra (blue), and Clus-
terFAST (red) to detect the breakpoints in the 13 ALK and KMT2A rearranged
cases in randomly down-sampled binary sequence alignment ﬁles. Squares
indicate the mean (over three random samples) sensitivity per tool, and
error bars indicate SE in the mean.
Translocation Detection by NGSIn this collection of sequenced cases, we were able to
detect KMT2A rearrangements with higher sensitivity than
ALK rearrangements (Supplemental Figure S2). At a down-
sampling rate of 0.5, we detected 100% of KMT2A rear-
rangements compared with 86% to 100% (range for three
bioinformatic tools) of ALK rearrangements. At a down-
sampling rate of 0.2, we detected 67% to 100% of
KMT2A rearrangements and 29% to 71% of ALK rear-
rangements. Finally, at a down-sampling rate of 0.1, we
detected 67% to 83% of KMT2A rearrangements and 14% to
43% of ALK rearrangements. Our reduced sensitivity to
detect ALK rearrangements was in part due to lower overall
unique coverage in a subset of the ALK rearranged samples,
likely secondary to lower DNA input levels; the cases with
low-input DNA levels had as few as two read pairs sup-
porting the breakpoint and so were not detectable after
down-sampling.Speciﬁcity of Translocation Detection
To evaluate the speciﬁcity of NGS for detection of ALK and
KMT2A rearrangement, we compared the results of the three
highly sensitive bioinformatic tools (Breakdancer, Hydra,
and ClusterFAST) on 77 cancers with no evidence by FISH
break-apart probes of ALK or KMT2A rearrangement.
Neither Breakdancer nor ClusterFAST found any SV >1 kb
involving ALK or KMT2A, resulting in 100% speciﬁcity
(95% CI, 95%e100%). Hydra identiﬁed no chromosomal
rearrangements involving ALK and four rearrangements
involving KMT2A, resulting in a speciﬁcity of 94.8% (95%
CI, 87%e98%). Of the four translocations identiﬁed by
Hydra, each was supported by only two discordant pairs,
and none involved a known partner of KMT2A.
We further evaluated the speciﬁcity of SV detection by
NGS compared with conventional methods by examining
the set of SV identiﬁed on the full 151-gene panel on the set
of six KMT2A-rearranged cases on which we had orthogonal
data on SV by routine cytogenetics. We examined both the
total number of SV >1 kb identiﬁed per case and, because
cytogenetics has limited resolution to detect small SV, theThe Journal of Molecular Diagnostics - jmd.amjpathol.orgnumber of unique interchromosomal translocations. Of the
six leukemias with KMT2A rearrangements, Hydra identi-
ﬁed the largest number of SVs: 25.5 total events per case
(range, 5 to 104), of which 4 (range, 2 to 6) were inter-
chromosomal. Breakdancer identiﬁed a mean of 16.2 events
per case (range, 6 to 22), of which 3 (range, 2 to 4) were
interchromosomal. Finally, ClusterFAST identiﬁed only a
mean of 2.8 events per case (range, 2 to 6), of which exactly
two per case were interchromosomal. Aside from the
KMT2A rearrangements described above (exactly two per
case), none of the additional interchromosomal rearrange-
ments were detected by cytogenetics and represent likely
false-positive results.
Design of Capture Probes Effects Speciﬁcity
Two versions of the capture panel were initially used for
ALK and KMT2A enrichment. We present data based on the
better-performing V2 design; however, it is of some interest
to compare this to our initial V1 design. In an effort to
maximize sensitivity, we initially targeted the entire KMT2A
gene, including introns (chromosome 11: 118307204 to
18397539; 90 kbp), and the telomeric half of ALK,
including introns (chromosome 2: 29415639 to 29456662;
41 kbp). In comparison, the V2 design captured a more
focused region based on previously reported ALK and
KMT2A breakpoints (all ALK exons plus introns 16 to 21,
5.4 kbp, and all KMT2A exons plus introns 7 to 12, 12.6
kbp), resulting in an over sevenfold reduction in capture
space. A total of six cases were sequenced on both the V1
and V2 panels, including two ALK rearranged cases and
four KMT2A rearranged cases, in addition to 96 ALK and
KMT2A FISH rearrangementenegative cases sequenced on
the V1 panel. The mean  SD coverage across the ALK and
KMT2A targeted regions was higher in V1 cases
(1608  651 for ALK and 1804  707 for KMT2A) than in
V2 cases. However, the breadth of coverage was lower, with
just 66% and 86% of nucleotide positions in the KMT2A and
ALK targeted regions, respectively, having at least 200
coverage. An unintended consequence of larger capture
areas was an increase in false-positive translocation reports.
Among the 96 negative control cases, we observed one or
more false-positive SV involving ALK or KMT2A in 61
cases using Hydra (36% speciﬁcity; 95% CI, 28%e46%), in
55 cases using Breakdancer (43% speciﬁcity; 95% CI,
33%e53%), and in only ﬁve cases using ClusterFAST
(95% speciﬁcity; 95% CI, 88%e98%).
Improved Speciﬁcity by Removal of Duplicate Reads
Although our initial analysis pipeline ignored previously
marked duplicate reads (ie, read pairs with the same start
positions), we sought to determine whether inclusion of
duplicate reads would increase the sensitivity of trans-
location detection or adversely affect the speciﬁcity. By
including duplicate reads we found that the false-positive413
Abel et alrate for most tools increased without a corresponding in-
crease in sensitivity. Using the six KMT2A rearranged
positive controls and including duplicate reads, we identi-
ﬁed a mean of 67, 25.5, and 2 interchromosomal rear-
rangements per case using Breakdancer, Hydra, and
ClusterFAST, respectively (Figure 5).
Discussion
In this study we used a set of seven FISH-positive ALK
rearranged cancers and six FISH/cytogenetics-positive
KMT2A rearranged leukemias to determine the sensitivity
of ALK and KMT2A rearrangement detection by targeted
NGS using DNA derived from formalin-ﬁxed tissue blocks.1
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Figure 5 Effect of duplicate reads. A: The Circos plot shows all trans-
location events within the 151 targeted genes on the panel in the six FISH-
positive KMT2A rearranged cases identiﬁed by Breakdancer (red lines) and
ClusterFAST (blue) when duplicate reads were not removed before analysis.
B: Box and whisker plot of log10 counts of all structural variants, inter-
chromosomal rearrangements, and ALK/KMT2A interchromsomal rear-
rangements, detected by Breakdancer (red) and ClusterFAST (blue) for all
reads (dark red/blue) and with duplicates removed (light red/blue).
414With an overall mean ALK coverage of 691 and KMT2A
coverage of 583 across all positive cases, we detected
seven of seven ALK rearranged cases (100%) and six of six
KMT2A rearranged leukemias (100%), by targeting only
ALK or KMT2A and not common partner genes with most
software tools. We compared the performance of three
publicly available translocation detection tools (Break-
dancer, CREST, Hydra) and one laboratory-derived tool
(ClusterFAST) and found similar sensitivities among
Breakdancer (13/13), Hydra (13/13), and ClusterFAST (13/
13) for detection of an ALK or KMT2A rearrangement using
FISH as a gold standard; in our series CREST had an overall
lower sensitivity (10/13). The exact reason for the observed
decreased sensitivity of CREST is unclear; however,
because of the reliance of CREST on information from soft-
clips, its performance will depend on the choice of align-
ment software. For example, we have reported previously
that the soft-clips produced by Novoalign tend to be shorter
than those produced by Burrows-Wheeler Aligner (http://
bio-bwa.sourceforge.net, last accessed May 22, 2014).23
We note that although the sensitivities of Breakdancer,
ClusterFAST, and Hydra were similar in this study, only
ClusterFAST outputs the exact breakpoint contig sequences,
allowing for simpliﬁed design of PCR primers for break-
point veriﬁcation.
Although targeted detection of translocations has been
reported by several groups, the clinically important false-
positive rate has not been addressed; we sought to formally
evaluate the speciﬁcity of translocation detection programs
and suggest optimal parameters for their use using a set of
77 clinical cancer specimens without ALK or KMT2A rear-
rangements by FISH. When duplicate reads were removed,
we found that both ClusterFAST and Breakdancer detected
no false-positive rearrangements (ALK or KMT2A rear-
rangements involving any gene), whereas Hydra reported
KMT2A rearrangements in four cases. We note that, by
design, the Hydra pipeline involves a sensitive realignment,
allowing Hydra to detect SV occurring in repetitive regions
or near SNVs; the tradeoff, however, is reduced speciﬁcity.
None of the four false-positive KMT2A rearrangements
involved a known translocation partner of KMT2A, and all
were supported by just two read pairs. However, among our
set of 13 cases, several validated structural variants involved
novel translocation partners or were supported by only two
read pairs. Thus ﬁltering on either of these criteria would
increase speciﬁcity but at the cost of reduced sensitivity.
Finally, in a set of cases positive by FISH for KMT2A
rearrangements and subjected to routine cytogenetics, we
determined that Hydra detected a mean of an additional two
interchromosomal translocations that were inconsistent with
cytogenetics, Breakdancer detected one additional inter-
chromosomal translocation per case, and ClusterFAST
detected no interchromosomal translocation inconsistent
with the cytogenetic ﬁndings. Although it is possible that
some of these may be true cryptic rearrangements unre-
solved by cytogenetics, most are likely false-positivejmd.amjpathol.org - The Journal of Molecular Diagnostics
Translocation Detection by NGSﬁndings. Thus, ClusterFAST provides improved speciﬁcity
in high-coverage targeted sequence data.
Although the prior analysis discarded duplicate reads, we
also considered the effect of including duplicate reads in the
analysis as a possible method to increase sensitivity and
found that Breakdancer and Hydra each produced an
increased number of false-positive rearrangements in the
ALK and KMT2A rearranged cases (67 and 25.5 per case,
respectively), whereas no difference was seen with Clus-
terFAST. These data support the idea that duplicate reads
should be marked and discarded during translocation anal-
ysis to maintain a high positive predictive value. We further
compared the effect of capture probe design on translocation
detection and found that by increasing the size of the capture
region sixfold to include all ALK and KMT2A introns/exons
(as opposed to selected introns that have been previously
reported to harbor translocations), the false-positive rate
increased markedly compared with FISH, resulting in
decreased speciﬁcities for Breakdancer (43%), Hydra
(36%), and ClusterFAST (95%). Most of these false-
positive results occurred in repeat regions, suggesting that
careful selection of capture regions is required for optimal
speciﬁcity.
Finally, we performed a random down-sampling experi-
ment to evaluate the sensitivity of breakpoint detection with
decreasing coverage levels. Although many factors,
including tumor heterogeneity, local coverage, mappability,
or presence of SNVs or indels near the breakpoint, will
inﬂuence sensitivity of detection by NGS, we are able to
make some generalizations. First, high levels of unique
coverage are needed for detection of gene rearrangements
by NGS: even with mean coverage levels of 1000 across
the full gene panel and mean coverage levels of >500
across the targeted rearrangement hotspots, uneven
coverage in the intronic regions still may result in low levels
of coverage in the vicinity of breakpoints and even lower (as
few as two in some cases) numbers of read pairs supporting
any breakpoint. In our experiment, for KMT2A rearranged
cases in which the percentage of rearrangement-positive
nuclei by FISH or cytogenetics was 90%, we observed a
sensitivity of 100% for random down-sampling rates of at
least 50%, corresponding to a mean coverage level over the
targeted rearrangement hotspots of 330. For ALK rear-
ranged cases where the mean tumor cellularity was 40%, a
sensitivity of 90% was estimated for random down-
sampling rates of 50%. This ﬁnding suggests that
coverage levels of at least 250 to 500 over the targeted
intronic regions should provide adequate detection of gene
rearrangements, although higher coverage may be necessary
in more heterogeneous samples. On the basis of these data,
we estimate that a tumor cellularity of 20% should yield an
approximate sensitivity of 90% for rearrangement detection,
provided the coverage in the targeted regions averages
600. Although we did not directly compare the effect of
DNA input quantity to rearrangement detection sensitivity,
we note that low-input DNA specimens (especiallyThe Journal of Molecular Diagnostics - jmd.amjpathol.orgthose <100 ng) generate fewer numbers of unique reads and
may adversely affect detection sensitivity. Finally, we note
that several areas of ALK and KMT2A had low overall
coverage that appeared to correlate with increased GC
content. Sensitivity may be increased in these areas by better
optimization of library preparation conditions or by the
addition of spike-in probes targeting areas of low
coverage.36
Although in this study perfect rearrangement sensitivity
and speciﬁcity were obtained by removing duplicate reads
and requiring at least two supporting reads, we caution that
this performance may not be generalizable to clinical labo-
ratory practice, given the variability in tumor cellularity,
input DNA levels, and sequencing coverage obtained in
clinical cases. We suggest that laboratories determine their
own sensitivity and speciﬁcity requirements for a given
sample type and adjust calling parameters accordingly. For
example, AMLs typically present with a high tumor cellu-
larity, facilitating rearrangement detection. In such cases,
laboratories may require a higher number of supporting
reads to increase speciﬁcity. On the other hand, in cases that
typically have lower tumor cellularity, such as lung carci-
nomas, fewer supporting reads may be required to maximize
sensitivity. In the latter case, false-positive rearrangements
could be evaluated by FISH or PCR.
NGS-based detection of DNA-level translocations,
although technically complex, has numerous advantages
over standard translocation detection methods, including
immunohistochemistry (IHC), RT-PCR, and FISH. IHC has
been proposed as a screening test for ALK rearrangements in
lung cancer and shows good concordance with FISH but
may be difﬁcult to interpret in cases of borderline expression
and, similar to RT-PCRebased ALK rearrangement detec-
tion, is not part of current testing guidelines.9,37 Interphase
FISH can be run on FFPE tissue, similar to NGS; however,
FISH does not provide single-nucleotide resolution of the
breakpoint and may be confounded by complex rearrange-
ments. Further, although FISH is inexpensive as a single
assay, in many diseases (eg, acute leukemias, myeloma, and
myelodysplastic syndrome) FISH panels composed of
several probes are performed, often resulting in costs of
several thousand dollars. In contrast, NGS-based trans-
location detection is capable of examining multiple loci for
gene rearrangements for minimal cost increase when used in
conjunction with gene panelebased NGS testing. In the case
of lung cancer and acute leukemias, where multiple genes
and exons are clinically tested for rearrangements and mu-
tations, including ALK, EGFR, KRAS, RET, ROS1, and
CEBPA, DNMT3A, FLT3, IDH1/2, KMT2A, NPM1, RARA,
and RUNX1, the use of such targeted gene panels has the
potential to decrease laboratory testing costs. Although
translocations may also be detected at the RNA level using
NGS-based RNA sequencing, this in general requires intact
RNA that may be difﬁcult to obtain on most surgical
resection specimens. Further, we note that some trans-
locations, including those that involve the immunoglobulin415
Abel et alheavy chain region, result in gene fusions that do not pro-
duce chimeric transcripts and would therefore not be
detectable by analysis of RNA fusions.
In addition to reducing testing costs by combining
translocation detection with gene mutation analysis, further
prognostic information may be gleaned from the elucidation
of exact rearrangement loci. For example, although response
to the ALK inhibitor crizotinib generally results in increased
progression-free survival in ALK rearranged lung cancers,
there is considerable heterogeneity in response.14 Among
six FISH-positive, ALK rearranged lung cancers, one case
contained a noncanonical breakpoint, occurring in ALK
intron 16 rather than intron 19. This rearrangement, which
leaves an intact ALK transmembrane domain, should not
result in constitutive dimerization of the ALK kinase domain
and consequent increase in its catalytic activity.11,38
Therefore, knowledge of the exact breakpoint sequence
may be clinically important in predicting treatment
response. In addition, knowledge of the somatically ac-
quired breakpoint sequence may allow for the monitoring of
minimal residual disease from plasma-derived cell free
DNA using patient- and breakpoint speciﬁc quantitative
PCR, as has been shown for other rearrangements.39
We report that recurrent ALK and KMT2A rearrangements
can be reliably detected at the DNA level from formalin-
ﬁxed clinical specimens by targeted, panel-based NGS
with similar sensitivity and speciﬁcity to FISH. Further,
NGS is capable of identifying translocation partners without
direct targeting of these partners. Finally, because NGS can
detect a full range of cancer-related mutations, including
single-nucleotide variants, insertions or deletions, and copy
number change, there are considerable efﬁciencies associ-
ated with NGS testing that result in decreased resource
expenditure compared with current piecemeal testing. These
results indicate that NGS-based diagnostics have the po-
tential to replace FISH as the preferred method for rear-
rangement detection in oncology testing.
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